Cellumed Receives Government Designation Certificate as an Excellent Corporate Research Institute

Cellumed announced on the 10th that it has been selected as a lead company for the ‘2023 Excellent Enterprise Research Institute Development Project (ATC+)’ organized by the Ministry of Trade, Industry and Energy, and received a designation certificate. The company will officially carry out a government-supported project related to improving the productivity of bone morphogenetic protein (BMP2).

In ATC+, Cellumed was recognized for its outstanding technology that increases the productivity of the core bio-material ‘BMP2’ by five times compared to the existing level. ATC+ is a national research and development project led by the Ministry of Trade, Industry and Energy that supports and fosters the R&D capabilities of research institutes affiliated with small and medium-sized enterprises. Selection is based on the growth potential of the research institute and its technology commercialization capabilities.

Cellumed holds numerous patented technologies related to BMP2. Based on the BMP2 it developed independently, the company plans to develop various new composite materials for bone grafts, including next-generation ‘dental bone graft materials’ and ‘spinal fusion bone graft materials’ with high efficacy and convenience that dramatically improve the shortcomings of existing products.

A Cellumed representative said, "With the selection for ATC+ as a turning point, we will strengthen our R&D capabilities in the bio business sector and accelerate performance growth by developing various new products utilizing core materials."

He added, "There was a temporary supply adjustment due to large-scale expansion in the first half of this year," emphasizing, "The effects of the expansion are expected to be fully realized from the second half of this year."

This content was produced with the assistance of AI translation services.